Fig. 3.
![Fig. 3. (Top panel) The effect of added APC on the APTT of plasma from the index patient with factor V Cambridge (Thr306; ▵) compared with patients heterozygous (○) and homozygous (•) for the Gln506 mutation and a normal control (Arg506; □). (Bottom panel) APC resistance of family members with (I.2 [▵] and II.1 [▴]) and without (I.1 [□] and II.2 [▪]) the Thr306 mutation.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/91/4/10.1182_blood.v91.4.1140/4/blod4043803.jpeg?Expires=1724230725&Signature=Y7tOxYWSb9EP1YGFIRSEfSmVwjit-tkyLt7k9r3qr4bOLchUeICi~fkOBK9CUq180nVlzd-kNB4OYUNfefDLH0pTomkc62lYEBuLcuz-V5FPWsr0ij5~rKWS9u3BzmyUxmxZktgy27Pg2d2b0wiwxZatRHzDsLs1ZPyX-r0cAW8qapUAXknSAhpl3BFqL-F9ZaCvOrbbr0jZjBnxYFZUiH9chnUJlMt94ecMTyW8obgzKpjr9IHeMwOAyvPWAwxxfjEoYvTqU~KTInZcrXQoGKq6~S7WuTddTUgRV8Grp-Ke6QFYjlVWDsO8TvzxlDqowEJ2NAYPpg4K4nxxp~j0-Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
(Top panel) The effect of added APC on the APTT of plasma from the index patient with factor V Cambridge (Thr306; ▵) compared with patients heterozygous (○) and homozygous (•) for the Gln506 mutation and a normal control (Arg506; □). (Bottom panel) APC resistance of family members with (I.2 [▵] and II.1 [▴]) and without (I.1 [□] and II.2 [▪]) the Thr306 mutation.
